BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 at HC Wainwright

BioXcel Therapeutics (NASDAQ:BTAI) had its price objective cut by HC Wainwright from $7.00 to $5.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.54) EPS.

BTAI has been the topic of a number of other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research note on Friday, August 30th. UBS Group dropped their target price on shares of BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th.

BioXcel Therapeutics Stock Performance

Shares of NASDAQ:BTAI opened at $0.58 on Monday. The stock has a market capitalization of $21.75 million, a price-to-earnings ratio of -0.11 and a beta of 0.28. BioXcel Therapeutics has a 1-year low of $0.51 and a 1-year high of $5.62. The company has a 50 day moving average price of $0.60 and a 200 day moving average price of $1.31.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.55. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.80 million. During the same period in the prior year, the business earned ($1.83) earnings per share. On average, sell-side analysts expect that BioXcel Therapeutics will post -1.84 EPS for the current fiscal year.

Institutional Investors Weigh In On BioXcel Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioXcel Therapeutics during the 2nd quarter valued at about $39,000. Rosalind Advisors Inc. purchased a new position in BioXcel Therapeutics during the second quarter valued at approximately $51,000. XTX Topco Ltd grew its position in BioXcel Therapeutics by 49.0% during the second quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock valued at $60,000 after purchasing an additional 15,291 shares in the last quarter. Virtu Financial LLC acquired a new position in BioXcel Therapeutics in the 4th quarter valued at approximately $176,000. Finally, Vanguard Group Inc. lifted its position in BioXcel Therapeutics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock worth $3,100,000 after buying an additional 9,912 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.